Intraductal Antibiotic During ERCP for Acute Cholangitis Treatment

Acute cholangitis is a severe infection in the biliary system, the network of ducts that carry bile from the liver to the gut. It's caused by blocked bile ducts and infected bile, and can quickly lead to a serious condition called sepsis if not treated promptly. The standard treatment involves systemic antibiotics and urgent biliary drainage, often through a procedure called endoscopic retrograde cholangiopancreatography (ERCP). However, the blockage might prevent the antibiotics from reaching the infection site effectively. This study aims to evaluate if delivering antibiotics directly into the bile ducts during ERCP, in addition to standard antibiotic therapy, can improve treatment outcomes in patients with acute cholangitis. During the study, participants will receive antibiotics both systemically and directly into the bile ducts during the ERCP procedure. The study then measures the effectiveness of this approach by monitoring changes in inflammatory markers, liver function tests, and vital signs. Inflammatory markers include total white cell count and C-reactive protein, while liver function tests assess various parameters such as bilirubin levels and enzyme activity. Vital signs like body temperature, blood pressure, and pulse rate are also monitored. These measurements are taken before the ERCP procedure and then 24-72 hours after the procedure to evaluate the treatment's impact.